News
Our Business
Case Study 2: DPC 961 – Form Change On A Fast Track Compound
DPC 961 (Fig. 6) was a development compound indicated for the treatment of HIV infections and was developed as a neutral molecule (Staszewski et al. 1999). The compound was designated as Biopharmaceut...
Developability Assessment
For lead compounds or candidate compounds, Crystal pharmatech can make an objective evaluation of the development potential and risks of drugs through comprehensive and accurate evaluation of the physicochemical properties of compounds, combined with a variety of mature development evaluation models and GastroPlus® software.
CATUG and Crystal Bio Establish Strategic Partnership, Launching “CATUG-Crystal” Joint Lab Dedicated to Advanced Nucleic Acid Analytical Services
CAMBRIDGE, Massachusetts & CRANBURY, New Jersey, February 21, 2024, – CATUG Inc. (CATUG) and Crystal Bio, a member of Crystal Pharmatech, announced today a long-term strategic partnership to prov...
Bioanalytical and Biomarker Services
With more than 100 years of combined industry experience of our leadership team and three GLP compliant laboratories, we are ready for all your current and emerging bioanalytical needs.
Applying PBPK and PBBM Across R&D: From Early Insights to Formulation
Applying PBPK and PBBM Across R&D: FromEarly Insights to FormulationDrug-delivery programs face recurring hurdles: frequent dosing, nighttimecoverage, and site-specific absorption. Controlled- and...
Mol2Med™ Developability Assessment: Material-Sparing, Rapid Studies, and Developability Strategies
From early developability to late-stage specifications—polymorph/salt-cocrystal strategy, SCXRD/MicroED solutions, solvent & pathway design, drug-product form control, ASD crystalline-form limits...
AAPS PharmSci 360
Crystal Pharmatech will be at AAPS Booth 3345 to share practical formulation work and approaches that keep early development on track. If you're building data packages for IND or optimizing a clin...
Subscribe to be the first to get the updates!
